Former FDA Commissioner Scott Gottlieb warns of a looming health crisis due to the recently passed Inflation Reduction Act. With 130 drugs already in shortage, including vital cancer treatments, patients’ lives are at risk. The Act’s limitations on drug prices hinder generic manufacturers from recouping costs, leading to further shortages. Gottlieb emphasizes the critical shortage of sterile injectable drugs and exposes Big Pharma’s failure to reinvest in manufacturing facilities, resulting in quality issues. The crisis is exemplified by the extreme scarcity of Ozempic, a crucial diabetes treatment. This medical catastrophe demands immediate attention and action to protect patients.
